DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,379,141 | +5.2% | 102,294 | +1.8% | 0.29% | +14.5% |
| Q2 2023 | $24,123,840 | -2.0% | 100,516 | +2.9% | 0.26% | -7.9% |
| Q1 2023 | $24,627,585 | +97818.9% | 97,713 | +3.1% | 0.28% | -12.6% |
| Q4 2022 | $25,151 | -99.9% | 94,761 | -1.0% | 0.32% | -13.1% |
| Q3 2022 | $24,734,000 | +7.8% | 95,761 | +5.8% | 0.37% | +5.5% |
| Q2 2022 | $22,952,000 | -7.8% | 90,534 | +6.7% | 0.35% | +16.8% |
| Q1 2022 | $24,888,000 | -10.2% | 84,848 | +0.7% | 0.30% | -8.6% |
| Q4 2021 | $27,727,000 | +9.4% | 84,273 | +1.2% | 0.32% | +5.2% |
| Q3 2021 | $25,356,000 | +10.2% | 83,287 | -2.9% | 0.31% | +8.4% |
| Q2 2021 | $23,010,000 | +17.7% | 85,744 | -1.3% | 0.28% | +10.5% |
| Q1 2021 | $19,548,000 | +2.2% | 86,847 | +0.9% | 0.26% | +1.6% |
| Q4 2020 | $19,124,000 | +5.6% | 86,089 | +2.4% | 0.25% | -9.6% |
| Q3 2020 | $18,110,000 | +20.5% | 84,105 | -1.0% | 0.28% | +6.8% |
| Q2 2020 | $15,023,000 | +30.4% | 84,957 | +2.0% | 0.26% | +14.8% |
| Q1 2020 | $11,525,000 | -8.7% | 83,269 | +1.2% | 0.23% | +15.7% |
| Q4 2019 | $12,629,000 | +6.1% | 82,283 | -0.1% | 0.20% | +7.0% |
| Q3 2019 | $11,898,000 | +1.3% | 82,377 | +0.2% | 0.18% | -0.5% |
| Q2 2019 | $11,746,000 | +6.2% | 82,183 | -1.9% | 0.19% | +2.2% |
| Q1 2019 | $11,064,000 | +27.1% | 83,808 | -0.7% | 0.18% | +5.8% |
| Q4 2018 | $8,702,000 | -5.4% | 84,391 | -0.3% | 0.17% | +3.6% |
| Q3 2018 | $9,194,000 | +8.4% | 84,609 | -1.5% | 0.17% | +3.1% |
| Q2 2018 | $8,480,000 | +2.0% | 85,931 | +1.2% | 0.16% | -2.4% |
| Q1 2018 | $8,316,000 | +5.2% | 84,937 | -0.3% | 0.16% | +3.1% |
| Q4 2017 | $7,904,000 | +7.9% | 85,150 | -0.2% | 0.16% | -0.6% |
| Q3 2017 | $7,322,000 | +8.0% | 85,363 | +6.3% | 0.16% | +3.9% |
| Q2 2017 | $6,780,000 | -5.5% | 80,338 | -4.2% | 0.16% | -10.4% |
| Q1 2017 | $7,173,000 | +2.0% | 83,870 | -7.2% | 0.17% | -6.5% |
| Q4 2016 | $7,034,000 | +0.5% | 90,359 | +1.2% | 0.18% | +0.5% |
| Q3 2016 | $7,002,000 | -14.6% | 89,321 | +10.0% | 0.18% | -12.4% |
| Q2 2016 | $8,198,000 | -6.3% | 81,171 | -12.0% | 0.21% | -11.8% |
| Q1 2016 | $8,753,000 | +3915.1% | 92,271 | +3833.1% | 0.24% | +3300.0% |
| Q4 2015 | $218,000 | -5.6% | 2,346 | -13.2% | 0.01% | 0.0% |
| Q2 2015 | $231,000 | – | 2,704 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |